Compare Cytokinetics Inc (CYTK) vs Medline Inc. Class A Common Stock (MDLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Medline Inc. Class A Common Stock — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Medline Inc. Class A Common Stock trades at $35.74 (market cap $31.36B). The key difference: Medline Inc. Class A Common Stock is far larger — about 3.6× Cytokinetics Inc's market cap, and Medline Inc. Class A Common Stock is more actively traded (10,191,251 versus 2,594,626). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Medline Inc. Class A Common Stock for 0 Days on average.
| CYTK | MDLN | |
|---|---|---|
Market Cap | $8.62B | $31.36B |
Volume | 2,594,626 | 10,191,251 |
Sector | Health | Health |
52-Week High | $87.26 | $49.99 |
52-Week Low | $54.76 | $31.64 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | $8.72B | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Medline Inc. Class A Common Stock
Medline provides medical-surgical products and supply-chain solutions for healthcare providers. Its portfolio and distribution network serve hospitals, clinics, long-term care facilities, and other care settings.
Read more on MDLN →
